生长抑素联合乌司他丁治疗中重症急性胰腺炎的临床效果评价

Clinical effect evaluation of somatostatin combined with ulinastatin in the treatment of moderate or severe acute pancreatitis

目的 观察生长抑素联合乌司他丁治疗中重症急性胰腺炎的临床效果。方法 52例中重症急性胰腺炎患者,随机分为对照组与试验组,每组26例。对照组患者在常规治疗的基础上采取生长抑素治疗,试验组患者在对照组的基础上加用乌司他丁治疗。比较两组患者治疗前、治疗4 d后、治疗7 d后的白细胞计数、C反应蛋白、血淀粉酶水平,腹痛消失时间及住院时间。结果 治疗前,两组患者的白细胞计数、C反应蛋白、血淀粉酶比较,差异无统计学意义(P>0.05);治疗4、7 d后,两组患者的白细胞计数、C反应蛋白、血淀粉酶均低于本组治疗前,差异有统计学意义(P<0.05)。且治疗4、7 d后,试验组患者的白细胞计数(9.12±2.45)×10~9/L、(7.03±1.08)×10~9/L均低于对照组的(10.72±2.88)×10~9/L、(8.59±2.26)×10~9/L, C反应蛋白(88.59±22.39)、(17.44±10.57)mg/L均低于对照组的(102.35±22.47)、(32.07±19.36)mg/L,血淀粉酶(392.47±279.55)、(91.44±65.17)U/L均低于对照组的(569.42±346.71)、(148.84±87.59)U/L,差异有统计学意义(P<0.05)。试验组患者的腹痛消失时间(4.55±2.49)d、住院时间(10.39±3.85)d均短于对照组的(6.20±2.35)、(14.45±4.74)d,差异有统计学意义(P<0.05)。结论 应用生长抑素联合乌司他丁治疗中重症急性胰腺炎效果显著,可有效改善患者的各项生命体征状况,患者的临床症状也明显消失,且缩短患者住院时间,对促进患者康复具有重要的作用,值得推广应用。

Objective To observe the clinical effect of somatostatin combined with ulinastatin in the treatment of moderate or severe acute pancreatitis.Methods A total of 52 patients with moderate to severe acute pancreatitis were randomly divided into control group and experimental group,with 26 cases in each group.Patients in the control group were treated with somatostatin on the basis of conventional treatment,and patients in the experimental group were treated with ulinastatin on the basis of the control group.The white blood cell count,C-reactive protein,blood amylase levels before treatment,after 4 d of treatment,and after 7 d of treatment,disappearance time of abdominal pain and hospitalization time were compared between the two groups.Results Before treatment,there was no statistically significant difference in white blood cell count,C-reactive protein and blood amylase between the two groups(P>0.05).After 4 and 7 d of treatment,the white blood cell count,C-reactive protein and blood amylase of the two groups were lower than those of this group before treatment,and the differences were statistically significant(P<0.05).After 4 and 7 d of treatment,the white blood cell counts in the experimental group were(9.12±2.45)×109/L and(7.03±1.08)×109/L,which were lower than(10.72±2.88)×109/L and(8.59±2.26)×109/L in the control group;the C-reactive protein in the experimental group were(88.59±22.39)and(17.44±10.57)mg/L,which were lower than(102.35±22.47)and(32.07±19.36)mg/L in the control group;the blood amylase in the experimental group were(392.47±279.55)and(91.44±65.17)U/L,which were lower than(569.42±346.71)and(148.84±87.59)U/L in the control group;all the differences were statistically significant(P<0.05).The disappearance time of abdominal pain(4.55±2.49)d and hospitalization time(10.39±3.85)d in the experimental group were shorter than(6.20±2.35)and(14.45±4.74)d in the control group,and the differences were statistically significant(P<0.05).Conclusion The application of somatostatin combined with ulinastatin has a significant effect in the treatment of moderate or severe acute pancreatitis.It can effectively improve the vital signs of patients,and the clinical symptoms of patients also disappeared significantly,and shorten the hospitalization time of patients,which has an important role in promoting the recovery of patients,and is worthy of promotion and application.